The majority of monocytes (1 x 10e9) were frozen in 90% A-plasma and 10% GMP-grade DMSO.

These monocyte come from an elutriation process from a metastatic lesion from stage III/IV melanoma patients and will be used for the generation of a vaccine and generation of tumour-lysated loaded DC.

These monocytes were extracted from a Leukapheresis product from cancer patients using elutriation.

These monocytes have been obtained from leukapheresis of tissue from patients with stage III or stage IV melanoma (tissue taken from a surgical resection of a melanotic lesion). They will subsequently be used to generate dendritic cells.

These monocytes were obtained after elutriation of a leukapheresis product (patients with stage III or stage IV melanoma) and are used to obtain dendritic cells from.

Monocytes were isolated from PBMC to generate dendritic cells.

Monocytes were cultured in RPMI 1640 medium (GIBCO BRL) supplemented with 2 mM L-glutamine (Sigma), 1% (vol/vol) non-essential amino acids, 100 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml of streptomycin (Gibco BRL) containing 10% (vol/vol) FCS (Hyclone).

1,25(OH)2D3 was added to the freshly isolated monocytes; this prevented the generation of IFN-DCs and directed already differentiated IFN-DCs toward a more immature stage.

Cells from healthy blood donors are separated into monocytes (and lymphocytes) by elutriation in a closed system (Elutra). [The two most monocyte-rich fractions collected contained > 80% monocytes, viability was > 95%.]